259 related articles for article (PubMed ID: 10602737)
1. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts.
Molina J; Martins-Filho O; Brener Z; Romanha AJ; Loebenberg D; Urbina JA
Antimicrob Agents Chemother; 2000 Jan; 44(1):150-5. PubMed ID: 10602737
[TBL] [Abstract][Full Text] [Related]
2. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi.
Molina J; Brener Z; Romanha AJ; Urbina JA
J Antimicrob Chemother; 2000 Jul; 46(1):137-40. PubMed ID: 10882704
[TBL] [Abstract][Full Text] [Related]
3. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.
Guedes PM; Urbina JA; de Lana M; Afonso LC; Veloso VM; Tafuri WL; Machado-Coelho GL; Chiari E; Bahia MT
Antimicrob Agents Chemother; 2004 Nov; 48(11):4286-92. PubMed ID: 15504854
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.
Urbina JA; Payares G; Contreras LM; Liendo A; Sanoja C; Molina J; Piras M; Piras R; Perez N; Wincker P; Loebenberg D
Antimicrob Agents Chemother; 1998 Jul; 42(7):1771-7. PubMed ID: 9661019
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.
Soeiro Mde N; de Souza EM; da Silva CF; Batista Dda G; Batista MM; Pavão BP; Araújo JS; Aiub CA; da Silva PB; Lionel J; Britto C; Kim K; Sulikowski G; Hargrove TY; Waterman MR; Lepesheva GI
Antimicrob Agents Chemother; 2013 Sep; 57(9):4151-63. PubMed ID: 23774435
[TBL] [Abstract][Full Text] [Related]
6. Fexinidazole: a potential new drug candidate for Chagas disease.
Bahia MT; de Andrade IM; Martins TA; do Nascimento ÁF; Diniz Lde F; Caldas IS; Talvani A; Trunz BB; Torreele E; Ribeiro I
PLoS Negl Trop Dis; 2012; 6(11):e1870. PubMed ID: 23133682
[TBL] [Abstract][Full Text] [Related]
7. Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.
Khare S; Liu X; Stinson M; Rivera I; Groessl T; Tuntland T; Yeh V; Wen B; Molteni V; Glynne R; Supek F
Antimicrob Agents Chemother; 2015 Oct; 59(10):6385-94. PubMed ID: 26239982
[TBL] [Abstract][Full Text] [Related]
8. Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.
Francisco AF; Lewis MD; Jayawardhana S; Taylor MC; Chatelain E; Kelly JM
Antimicrob Agents Chemother; 2015 Aug; 59(8):4653-61. PubMed ID: 26014936
[TBL] [Abstract][Full Text] [Related]
9. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice.
Diniz LF; Mazzeti AL; Caldas IS; Ribeiro I; Bahia MT
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555633
[TBL] [Abstract][Full Text] [Related]
10. Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease.
Maldonado RA; Molina J; Payares G; Urbina JA
Antimicrob Agents Chemother; 1993 Jun; 37(6):1353-9. PubMed ID: 8328786
[TBL] [Abstract][Full Text] [Related]
11. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease.
Araújo MS; Martins-Filho OA; Pereira ME; Brener Z
J Antimicrob Chemother; 2000 Jun; 45(6):819-24. PubMed ID: 10837436
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease.
Urbina JA; Payares G; Sanoja C; Lira R; Romanha AJ
Int J Antimicrob Agents; 2003 Jan; 21(1):27-38. PubMed ID: 12507835
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains.
Cencig S; Coltel N; Truyens C; Carlier Y
Int J Antimicrob Agents; 2012 Dec; 40(6):527-32. PubMed ID: 23063742
[TBL] [Abstract][Full Text] [Related]
14. Successful Aspects of the Coadministration of Sterol 14α-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi.
Guedes-da-Silva FH; Batista DDGJ; Da Silva CF; Pavão BP; Batista MM; Moreira OC; Souza LRQ; Britto C; Rachakonda G; Villalta F; Lepesheva GI; Soeiro MNC
ACS Infect Dis; 2019 Mar; 5(3):365-371. PubMed ID: 30625275
[TBL] [Abstract][Full Text] [Related]
15. In vivo susceptibility to benznidazole of Trypanosoma cruzi strains from the western Brazilian Amazon.
Teston AP; Monteiro WM; Reis D; Bossolani GD; Gomes ML; de Araújo SM; Bahia MT; Barbosa MG; Toledo MJ
Trop Med Int Health; 2013 Jan; 18(1):85-95. PubMed ID: 23130989
[TBL] [Abstract][Full Text] [Related]
16. Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi.
Puente V; Demaria A; Frank FM; Batlle A; Lombardo ME
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006764. PubMed ID: 30240395
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility to benznidazole, nifurtimox and posaconazole of Trypanosoma cruzi isolates from Paraguay.
Acosta N; Yaluff G; López E; Bobadilla C; Ramírez A; Fernández I; Escobar P
Biomedica; 2020 Dec; 40(4):749-763. PubMed ID: 33275352
[TBL] [Abstract][Full Text] [Related]
18. Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following Trypanosoma cruzi infection: A pre-clinical study.
Mazzeti AL; Diniz LF; Gonçalves KR; Nascimento AFS; Spósito PAF; Mosqueira VCF; Machado-Coelho GLL; Ribeiro I; Bahia MT
Biochem Pharmacol; 2018 Feb; 148():213-221. PubMed ID: 29309767
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide donor trans-[RuCl([15]aneN)NO] as a possible therapeutic approach for Chagas' disease.
Guedes PM; Oliveira FS; Gutierrez FR; da Silva GK; Rodrigues GJ; Bendhack LM; Franco DW; Do Valle Matta MA; Zamboni DS; da Silva RS; Silva JS
Br J Pharmacol; 2010 May; 160(2):270-82. PubMed ID: 20128813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
